NCT07051187View on ClinicalTrials.gov

A Trial to Evaluate the Efficacy and Safety of WGc0201 in Patients With Chronic Hepatitis B Virus Infection

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

July 30, 2025

Primary Completion Date

July 30, 2026

Study Completion Date

July 30, 2027

Conditions

Chronic Hepatitis B Virus (Hbv)

Interventions

DRUG

WGc0201

Wgc0201 will be administered by intramuscular route, with a total of 9 doses.

All Listed Sponsors

collaborator

West China Hospital

OTHER

lead

Jiyan Liu

OTHER